Consumers Want Brand Relationships With Benefits
14.9.2023 10:00:00 EEST | Business Wire | Press release
Mobile app experience company Airship has released data from its latest annual global survey showing that consumers want to be wooed and are willing to share their personal details with their favourite brands: 77% of UK consumers said they would share their interests relevant to a brand for personalised interactions and special incentives.
So what are consumers looking for in a prospective brand partner? Flowers and chocolate? Not necessarily. The “Mobile Consumer 2023” survey, commissioned by Airship and conducted in partnership with Sapio Research, among 11,000 consumers globally, found that consumers typically turn to apps to simplify their lives. Rather than deals and loyalty rewards, the top reasons customers keep coming back to apps are “ease of use” (42%) and “simplifies my life” (29%), while “saves me money” (23%) was the fourth main reason. Convenience is everything.
Consent and value are important to every relationship. The survey revealed that consumers are most willing to receive mobile app notifications in exchange for “immediate discounts or loyalty reward points” (47%) or “order confirmation and receipts” (28%). For comparison, “personalised offers based on browsing behaviour or past purchases” and “special offers triggered by location” saw the most growth year-over-year as motivators to opt-in to brand communications on smartphones, followed by “immediate discounts.”
Personal data and notification opt in are incredibly valuable to brands, as it empowers them to personalise offers and app experiences to each individual. But marketers need to tread carefully, or else they may come off as creepy: “predictive suggestions based on everything a brand knows about you” ranked as the least useful form of personalisation, favoured by just 21% of UK consumers.
Also, much like any date, first and second impressions are everything: 49% of UK consumers will decide whether to delete an app after just a couple of uses. And with plenty of fish in the sea, the top reason to delete apps is to free up phone storage (34%).
To avoid deletion, brands need to swiftly establish an exchange of respect and reward with new app customers — qualities that are fundamental to any long-term relationship. They need to clearly communicate how they will improve a customer’s life, demonstrate their value and deliver on their promises. If they fail, they are likely to be dumped and left unfulfilled.
“These findings show brands can build valuable, long-term customer relationships if they master great app experiences that respect and reward them,” says Tom Butta, chief strategy and marketing officer at Airship. “Like any successful long-term relationship, this requires understanding their needs and creating mutually beneficial exchanges in their moments of attention.”
To read the full report, including the key findings, recommendations and further data from Airship’s 2023 mobile consumer survey, please click here.
Methodology
The survey was completed in partnership with Sapio Research among more than 11,000 consumers, age 18 and older in the U.S., Canada, UK, France, Germany, South Africa, Singapore, Thailand, Indonesia and Brazil. Overall results are accurate to ±0.9% at a 95% confidence level.
About Airship
No one knows more, does more, or cares more than Airship when it comes to helping brands master mobile app experience (MAX).
From the beginning of apps, Airship powered the first commercial messages and then expanded its data-led approach to all re-engagement channels (mobile wallet, SMS, email), app UX experimentation, no-code native app experience creation and App Store Optimization (ASO).
Having powered trillions of mobile app interactions for thousands of global brands, Airship’s technology and deep industry expertise have enabled apps to become the digital center of customer experience, brand loyalty and monetization.
With the Airship App Experience Platform and Gummicube’s ASO technology and expertise, brands now have a complete set of solutions to optimise the entire mobile app customer journey – from the point of discovery to loyalty – driving greater value for everyone involved.
For more information, visit www.airship.com, read our blog or follow us on Twitter, LinkedIn and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230914103665/en/
Contact information
Media Contact
EMEA:
Ana Williams
Airship
+44 (0)20 3405 5160
press@airship.com
Pauline Delorme
Tyto PR
+44 (0)20 3934 8882
Airship@tytopr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
